Antibiotics—From There to Where?

David M. Shlaes, Patricia A. Bradford

Abstract


To fully appreciate the importance of antibiotics to everyday life, we must step back to the edge of the pre-antibiotic era when these lifesaving drugs were first introduced into clinical use.


Keywords


antibiotic; antibiotic resistance; Pneumonia; Endocarditis; bacteria

Full Text:

HTML PDF

References


1. Hoyne AL, Wolf A, Prim L. Fatality rates in the treatment of 998 erysipelas patients: The influence of sulfanilamide. Journal of the American Medical Association. 1939;113(26):2279-81. doi: 10.1001/jama.1939.02800510001001

2. Bullowa J. The course, symptoms and physical findings, The Management of Pneumonias. New York: Oxford University Press; 1937.

3. Austrian R, Gold J. Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia. Ann Intern Med. 1964;60:759-76. PubMed PMID: 14156606.

4. Flippin HF, Lockwood JS, Pepper D, Schwartz L. The treatment of pneumococcic pneumonia with sulfapyridine: A progress report on observations in 100 cases. Journal of the American Medical Association. 1939;112(6):529-34. doi: 10.1001/jama.1939.02800060045009

5. Meakins JC, Hanson FR. The Treatment of Pneumococcic Pneumonia with Sulfapyridine. Can Med Assoc J. 1939;40(4):333-6. PubMed PMID: 20321297. PubMed Central PMCID: 537092.

6. Administration FD. Issues in Clinical Trial Design for Community Acquired Bacterial Pneumonia 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM195620.pdf

7. Osler W. The Gulstonian Lectures, on Malignant Endocarditis. Br Med J. 1885;1(1262):467-70. PubMed PMID: 20751186. PubMed Central PMCID: 2255866.

8. Watanakunakorn C, Burkert T. Infective endocarditis at a large community teaching hospital, 1980-1990. A review of 210 episodes. Medicine (Baltimore). 1993;72(2):90-102. PubMed PMID: 8479327.

9. Schlaes DM. Antibiotics: The Perfect Storm. Heidelberg, London, New York: Springer Dordrecht; 2010.

10. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. JAMA. 1999;281(1):61-6. PubMed PMID: 9892452.

11. O’Neill J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations: The Review on Antimicrobial Resistance; 2016. Available from: https://amr-review.org

12. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, Aboderin AO, Al-Abri SS, Awang Jalil N, Benzonana N, Bhattacharya S, Brink AJ, Burkert FR, Cars O, Cornaglia G, Dyar OJ, Friedrich AW, Gales AC, Gandra S, Giske CG, Goff DA, Goossens H, Gottlieb T, Guzman Blanco M, Hryniewicz W, Kattula D, Jinks T, Kanj SS, Kerr L, Kieny M-P, Kim YS, Kozlov RS, Labarca J, Laxminarayan R, Leder K, Leibovici L, Levy-Hara G, Littman J, Malhotra-Kumar S, Manchanda V, Moja L, Ndoye B, Pan A, Paterson DL, Paul M, Qiu H, Ramon-Pardo P, Rodríguez-Baño J, Sanguinetti M, Sengupta S, Sharland M, Si-Mehand M, Silver LL, Song W, Steinbakk M, Thomsen J, Thwaites GE, van der Meer JWM, Van Kinh N, Vega S, Villegas MV, Wechsler-Fördös A, Wertheim HFL, Wesangula E, Woodford N, Yilmaz FO, Zorzet A. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases. 2017. doi: 10.1016/S1473-3099(17)30753-3

13. Gomez J, Simarro E, Banos V, Requena L, Ruiz J, Garcia F, Canteras M, Valdes M. Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 1999;18(5):358-61. PubMed PMID: 10421044.

14. Zarrilli R, Crispino M, Bagattini M, Barretta E, Di Popolo A, Triassi M, Villari P. Molecular Epidemiology of Sequential Outbreaks of Acinetobacter baumannii in an Intensive Care Unit Shows the Emergence of Carbapenem Resistance. Journal of Clinical Microbiology. 2004;42(3):946-53. doi: 10.1128/jcm.42.3.946-953.2004

15. Sung JY, Koo SH, Kim S, Kwon GC. Emergence of Acinetobacter pittii harboring New Delhi metallo-beta-lactamase genes in Daejeon, Korea. Ann Lab Med. 2015;35(5):531-4. PubMed PMID: 26206691. PubMed Central PMCID: PMC4510507. doi: 10.3343/alm.2015.35.5.531

16. Qureshi ZA, Hittle LE, O’Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60(9):1295-303. PubMed PMID: 25632010. PubMed Central PMCID: PMC4462660. doi: 10.1093/cid/civ048

17. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74(12):1315-33. PubMed PMID: 25091170. PubMed Central PMCID: PMC4258832. doi: 10.1007/s40265-014-0267-8

18. ECDC. Surveillance Atlas of Infectious Disease 2017 [27-Jul-2017]. Available from: http://atlas.ecdc.europa.eu/public/index.aspx

19. Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, Leblebicioglu H, Fisher D, Álvarez-Moreno C, Khader IA, Del Rocío González Martínez M, Cuellar LE, Navoa-Ng JA, Abouqal R, Guanche Garcell H, Mitrev Z, Pirez García MC, Hamdi A, Dueñas L, Cancel E, Gurskis V, Rasslan O, Ahmed A, Kanj SS, Ugalde OC, Mapp T, Raka L, Yuet Meng C, Thu LTA, Ghazal S, Gikas A, Narváez LP, Mejía N, Hadjieva N, Gamar Elanbya MO, Guzmán Siritt ME, Jayatilleke K. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. American Journal of Infection Control. 2012;40(5):396-407. doi: 10.1016/j.ajic.2011.05.020

20. Gill JS, Arora S, Khanna SP, Kumar KVSH. Prevalence of Multidrug-resistant, Extensively Drug-resistant, and Pandrug-resistant Pseudomonas aeruginosa from a Tertiary Level Intensive Care Unit. Journal of Global Infectious Diseases. 2016;8(4):155-9. PubMed PMID: PMC5126754. doi: 10.4103/0974-777X.192962

21. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello J, Chastre J, Antonelli M, Welte T, Clair B, Ostermann H, Calbo E, Torres A, Menichetti F, Schramm GE, Menon V. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care. 2015;19(1):219. doi: 10.1186/s13054-015-0926-5

22. Tam VH, Rogers CA, Chang K-T, Weston JS, Caeiro J-P, Garey KW. Impact of Multidrug-Resistant Pseudomonas aeruginosa Bacteremia on Patient Outcomes. Antimicrobial Agents and Chemotherapy. 2010;54(9):3717-22. PubMed PMID: PMC2935002. doi: 10.1128/AAC.00207-10

23. Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA. Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2016;60(2):1067-78. doi: 10.1128/aac.02379-15

24. Kazmierczak KM, Biedenbach DJ, Hackel M, Rabine S, de Jonge BLM, Bouchillon SK, Sahm DF, Bradford PA. Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam. Antimicrobial Agents and Chemotherapy. 2016;60(8):4490-500. doi: 10.1128/aac.00107-16

25. Van der Bij AK, Van Mansfeld R, Peirano G, Goessens WH, Severin JA, Pitout JD, Willems R, Van Westreenen M. First outbreak of VIM-2 metallo- b-lactamase-producing Pseudomonas aeruginosa in The Netherlands: microbiology, epidemiology and clinical outcomes. Int J Antimicrob Agents. 2011;37(6):513-8. PubMed PMID: 21497065. doi: 10.1016/j.ijantimicag.2011.02.010

26. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases. 2013;13(9):785-96. doi: 10.1016/S1473-3099(13)70190-7

27. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA. 1999;281(6):517-23. PubMed PMID: 10022107.

28. Valenza G, Nickel S, Pfeifer Y, Pietsch M, Voigtlander E, Lehner-Reindl V, Holler C. Prevalence and genetic diversity of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in nursing homes in Bavaria, Germany. Vet Microbiol. 2017;200:138-41. PubMed PMID: 26494113. doi: 10.1016/j.vetmic.2015.10.008

29. Canton R, Gonzalez-Alba JM, Galan JC. CTX-M Enzymes: Origin and Diffusion. Front Microbiol. 2012;3:110. PubMed PMID: 22485109. PubMed Central PMCID: PMC3316993. doi: 10.3389/fmicb.2012.00110

30. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, Rahal JJ, Brooks S, Cebular S, Quale J. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 b-lactamases in New York City. Clin Infect Dis. 2004;39(1):55-60. PubMed PMID: 15206053. doi: 10.1086/421495

31. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, Segre JA. Tracking a Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae with Whole-Genome Sequencing. Science Translational Medicine. 2012;4(148):148ra16-ra16. doi: 10.1126/scitranslmed.3004129

32. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases. 2010;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2

33. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med. 1988;319(3):157-61. PubMed PMID: 2968517. doi: 10.1056/nejm198807213190307

34. Sahm DF, Kissinger J, Gilmore MS, Murray PR, Mulder R, Solliday J, Clarke B. In vitro susceptibility studies of vancomycin-resistant E nterococcus faecalis. Antimicrobial Agents and Chemotherapy. 1989;33(9):1588-91. doi: 10.1128/aac.33.9.1588

35. Kirst HA, Thompson DG, Nicas TI. Historical Yearly Usage of Vancomycin. Antimicrobial Agents and Chemotherapy. 1998;42(5):1303-4.

36. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34(1):1-14. PubMed PMID: 23221186. doi: 10.1086/668770

37. ECDC. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2017.

38. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011. PubMed PMID: 18947320. doi: 10.1086/591861

39. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 2010;54(5):1670-7. doi 10.1128/aac.00019-10

40. Albrich WC, Harbarth S. Health-care workers: source, vector, or victim of MRSA? Lancet Infect Dis. 2008;8(5):289-301. PubMed PMID: 18471774. doi: 10.1016/s1473-3099(08)70097-5

41. Sader HS, Mendes RE, Streit JM, Flamm RK. Antimicrobial Susceptibility Trends Among Staphylococcus aureus from United States Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program (2010-2016). Antimicrob Agents Chemother. 2017. PubMed PMID: 28630196. doi: 10.1128/aac.01043-17

42. Nakamura A, Miyake K, Misawa S, Kuno Y, Horii T, Hori S, Kondo S, Tabe Y, Ohsaka A. Association between antimicrobial consumption and clinical isolates of methicillin-resistant Staphylococcus aureus: a 14-year study. J Infect Chemother. 2012;18(1):90-5. PubMed PMID: 21947660. doi: 10.1007/s10156-011-0302-6

43. Zuma AV, Lima DF, Assef AP, Marques EA, Leao RS. Molecular characterization of methicillin-resistant Staphylococcus aureus isolated from blood in Rio de Janeiro displaying susceptibility profiles to non-beta-lactam antibiotics. Braz J Microbiol. 2017;48(2):237-41. PubMed PMID: 28108350. PubMed Central PMCID: PMC5470436. doi: 10.1016/j.bjm.2016.09.016

44. Jiménez-Truque N, Saye EJ, Soper N, Saville BR, Thomsen I, Edwards KM, Creech CB. Longitudinal Assessment of Colonization With Staphylococcus aureus in Healthy Collegiate Athletes. Journal of the Pediatric Infectious Diseases Society. 2016;5(2):105-13. doi: 10.1093/jpids/piu108

45. CDC. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants–Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. MMWR. 2003;52:793-5.

46. Unemo M, Shafer WM. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clinical Microbiology Reviews. 2014;27(3):587-613. doi: 10.1128/cmr.00010-14

47. Patrick D, Shaw C, Rekart M. Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in British Columbia: an imported phenomenon. Canada communicable disease report—Relevé des maladies transmissibles au Canada. 1995;21(15):137.

48. Iverson CJ, Wang SA, Lee MV, Ohye RG, Trees DL, Knapp JS, Effler PV, O’Connor N P, Levine WC. Fluoroquinolone resistance among Neisseria gonorrhoeae isolates in Hawaii, 1990-2000: role of foreign importation and increasing endemic spread. Sex Transm Dis. 2004;31(12):702-8. PubMed PMID: 15608583.

49. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother. 2009;10(4):555-77. PubMed PMID: 19284360. PubMed Central PMCID: PMC2657229. doi: 10.1517/14656560902731993

50. Ito M, Yasuda M, Yokoi S, Ito S-i, Takahashi Y, Ishihara S, Maeda S-i, Deguchi T. Remarkable Increase in Central Japan in 2001-2002 of Neisseria gonorrhoeae Isolates with Decreased Susceptibility to Penicillin, Tetracycline, Oral Cephalosporins, and Fluoroquinolones. Antimicrobial Agents and Chemotherapy. 2004;48(8):3185-7. doi: 10.1128/aac.48.8.3185-3187.2004

51. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7(12):1401-22. PubMed PMID: 23231489. PubMed Central PMCID: PMC3629839. doi: 10.2217/fmb.12.117

52. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG. Effect of Introduction of the Pneumococcal Conjugate Vaccine on Drug-Resistant Streptococcus pneumoniae. New England Journal of Medicine. 2006;354(14):1455-63. PubMed PMID: 16598044. doi: 10.1056/NEJMoa051642

53. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure. Antimicrobial Agents and Chemotherapy. 2012;56(3):1273-80. doi: 10.1128/aac.05760-11

54. Lynch JP, Zhanel GG. Streptococcus pneumoniae: Epidemiology, Risk Factors, and Strategies for Prevention. Semin Respir Crit Care. 2009;30(2):189-209.

55. Musser JM. Molecular population genetic analysis of emerged bacterial pathogens: selected insights. Emerging Infectious Diseases. 1996;2(1):1-17. PubMed PMID: PMC2639800.

56. Lee NY, Song JH, Kim S, Peck KR, Ahn KM, Lee SI, Yang Y, Li J, Chongthaleong A, Tiengrim S, Aswapokee N, Lin TY, Wu JL, Chiu CH, Lalitha MK, Thomas K, Cherian T, Perera J, Yee TT, Jamal F, Warsa UC, Van PH, Carlos CC, Shibl AM, Jacobs MR, Appelbaum PC. Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis. 2001;32(10):1463-9. PubMed PMID: 11317248. doi: 10.1086/320165

57. Hashida K, Shiomori T, Hohchi N, Ohkubo J, Ohbuchi T, Mori T, Suzuki H. Nasopharyngeal Streptococcus pneumoniae carriage in Japanese children attending day-care centers. Int J Pediatr Otorhinolaryngol. 2011;75(5):664-9. PubMed PMID: 21371759. doi: 10.1016/j.ijporl.2011.02.005

58. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, O’Brien KL, Campbell H, Black RE. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-16. PubMed PMID: 23582727. doi: 10.1016/s0140-6736(13)60222-6

59. Huttner B, Harbarth S, Nathwani D, Policies ESGfA. Success stories of implementation of antimicrobial stewardship: a narrative review. Clin Microbiol Infect. 2014;20(10):954-62. PubMed PMID: 25294340. doi: 10.1111/1469-0691.12803

60. Aldeyab MA, Harbarth S, Vernaz N, Kearney MP, Scott MG, Darwish Elhajji FW, Aldiab MA, McElnay JC. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings. Br J Clin Pharmacol. 2012;74(1):171-9. PubMed PMID: 22150975. PubMed Central PMCID: 3394142. doi: 10.1111/j.1365-2125.2011.04161.x

61. CDC. Antibiotic Use in the United States, 2017: Progress and Opportunities. Atlanta, GA: US Department of Health and Human Services, CDC; 2017 2017.

62. European Centre for Disease P, Control, European Food Safety A, European Medicines A. ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. EFSA Journal. 2017;15(7):e04872-n/a. doi: 10.2903/j.efsa.2017.4872

63. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8. PubMed PMID: 26603172. doi: 10.1016/S1473-3099(15)00424-7

64. Luepke KH, Mohr JF, 3rd. The antibiotic pipeline: reviving research and development and speeding drugs to market. Expert Rev Anti Infect Ther. 2017;15(5):425-33. PubMed PMID: 28306360. doi: 10.1080/14787210.2017.1308251

65. CDC. Drug Resistance Threats: Centers for Disease Control; 2017. Available from: https://www.cdc.gov/drugresistance/biggest_threats.html

66. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81. PubMed PMID: 18419525. doi: 10.1086/533452

67. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis: WHO/EMP/IAU/2017.12; Geneva: World Health Organization; 2017.

68. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2007;6(1):29-40. PubMed PMID: 17159923. doi: 10.1038/nrd2201

69. Shlaes DM, Sahm D, Opiela C, Spellberg B. The FDA reboot of antibiotic development. Antimicrob Agents Chemother. 2013;57(10):4605-7. PubMed PMID: 23896479. PubMed Central PMCID: 3811409. doi: 10.1128/AAC.01277-13

70. Rex JH, Goldberger M, Eisenstein BI, Harney C. The evolution of the regulatory framework for antibacterial agents. Ann NY Acad Sci. 2014;1323:11-21. PubMed PMID: 24797794. PubMed Central PMCID: 4265259. doi: 10.1111/nyas.12441

71. Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, Dudley MN, Dane A. Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance. Clin Infect Dis. 2017;65(1):141-6. PubMed PMID: 29017263. doi: 10.1093/cid/cix246

72. Shlaes DM. Clinical Development for the Discovery Scientist in Topics in Medicinal Chemistry. Springer; 2017.

73. National Academies of Sciences E, Medicine. Making Medicines Affordable: A National Imperative. Augustine NR, Madhavan G, Nass SJ, editors. Washington, DC: The National Academies Press; 2017. 240 p.

74. Daniel GW, McClellan MB, Schneider M, Qian J, Lavezzari G, Graffenreid Ed. Value-based strategies for encouraging new development of antimicrobial drugs: Duke-Margolis Center for Health Policy; 2017. Available from: https://healthpolicy.duke.edu/PAVE

75. Barrett L. Antibiotic Markets and SPLU—Guest Blogger—Lew Barrett 2012. Available from: http://antibiotics-theperfectstorm.blogspot.com/2012/03/antibiotic-markets-and-splu-guest.html

76. A New Pathway for Antibiotic Innovation Exploring Drug Development for Limited Populations: Pew Charitable Trusts; 2013. Available from: http://www.pewtrusts.org/~/media/assets/2014/06/25/a-new-pathway-for-antibiotic-innovation/antibioticstranscriptpdf.pdf

77. van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG, Jr., Paterson DL, Bonomo RA, Evans S, Antibacterial Resistance Leadership G. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163-71. PubMed PMID: 29020404. doi: 10.1093/cid/cix783

78. Shlaes DM, Gerding DN, John JF, Jr., Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE, Jr., Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25(3):584-99. PubMed PMID: 9314444.

79. Prevention CfDCa. Core Elements of Hospital Antibiotic Stewardship Programs: Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/antibiotic-use/healthcare/implementation/core-elements.html

80. Richter MF, Drown BS, Riley AP, Garcia A, Shirai T, Svec RL, Hergenrother PJ. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature. 2017;545(7654):299-304. PubMed PMID: 28489819. PubMed Central PMCID: 5737020. doi: 10.1038/nature22308

81. Schlaes DM. The Broken Antibiotics Market Claims Another Victim: Antibiotics—The Perfect Storm; 2017.

82. Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, a Public Health Crisis Brews: Infectious Disease Society of America; 2004.

83. Mossialos EM, Chantal M.; Edwards, Suzanne; Berenson, Julia; Gemmill-Toyama, Marin, Brogan, David. Policies and incentives for promoting innovation in antibiotic research: The European Observatory on Health Systems and Policies; 2009. Available from: http://www.euro.who.int/__data/assets/pdf_file/0011/120143/E94241.pdf

84. Eichberg MJ. Public funding of clinical-stage antibiotic development in the United States and European Union. Health Secur. 2015;13(3):156-65. PubMed PMID: 26042859. PubMed Central PMCID: 4486734. doi: 10.1089/hs.2014.0081

85. Outterson K, Rex JH, Jinks T, Jackson P, Hallinan J, Karp S, Hung DT, Franceschi F, Merkeley T, Houchens C, Dixon DM, Kurilla MG, Aurigemma R, Larsen J. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. Nat Rev Drug Discov. 2016;15(9):589-90. PubMed PMID: 27469032. doi: 10.1038/nrd.2016.155

86. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33. PubMed PMID: 26928437. doi: 10.1016/j.jhealeco.2016.01.012

87. Outterson K, McDonnell A. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. Health Aff (Millwood). 2016;35(5):784-90. PubMed PMID: 27140983. doi: 10.1377/hlthaff.2015.1139

88. Towse A, Hoyle CK, Goodall J, Hirsch M, Mestre-Ferrandiz J, Rex JH. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation. Health Policy. 2017;121(10):1025-30. PubMed PMID: 28888660. doi: 10.1016/j.healthpol.2017.07.011

89. Ferraro JST, Adrian; Mestre-Ferrandiz, Jorge. Incentives for New Drugs to Tackle Anti-Microbial Resistance: Office of Health Economics; 2017. Available from: https://www.ohe.org/publications/incentives-new-drugs-tackle-anti-microbial-resistance

90. Ardal C, Rottingen JA, Opalska A, Van Hengel AJ, Larsen J. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis. 2017;65(8):1378-82. PubMed PMID: 29017240. doi: 10.1093/cid/cix526

91. HHS accelerates development of first Ebola vaccines and drugs: U.S. Department of Health & Human Services; 2017. Available from: https://www.hhs.gov/about/news/2017/09/29/hhs-accelerates-development-first-ebola-vaccines-and-drugs.html

92. Årdal C, Findlay D, Savic M, Carmeli Y, Gyssens I, Laxminarayan R, Outterson K, Rex JH. Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access: Drive AB; 2018. Available from: http://drive-ab.eu/wp-content/uploads/2018/01/DRIVE-AB-Final-Report-Jan2018.pdf


Article Level Metrics

Refbacks

  • There are currently no refbacks.




Copyright (c) 2018 David Shlaes

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

© Pathogens and Immunity 2018

Case Western Reserve University; Division of Infectious Diseases

10900 Euclid Ave.; Mailstop 4984; Cleveland, OH 44106

(216) 368-6317; ISSN: 2469-2964; info@paijournal.com